Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.
Ajinomoto Althea, Inc. announced on Sept. 19, 2017 that the company will open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility in San Diego, CA. The facility is designed to develop, manufacture, test, and release HPPs including antibody drug conjugates, highly potent APIs, and other complex formulations of highly potent drugs.
The company currently offers process development and analytical services to clients from the facility and will be open for GMP bioconjugation and complex formulation in November 2017. Full manufacturing services, including high containment fill and finish, will commence in Q4 2018, as reported in a press statement on Sept. 19, 2017.
The company also announced that it secured its first manufacturing contract for the new facility.
Source: Ajinomoto Althea
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.